Pharmacometabolomics in TB Meningitis – understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid

Jeffrey M. Collins¹, Maia Kipiani^{2,3,4}, Yutong Jin⁵, Ashish A. Sharma⁶, Jeffrey A. Tomalka⁶, Teona Avaliani², Mariam Gujabidze², Tinatin Bakuradze², Shorena Sabanadze², Zaza Avaliani^{2,7}, Henry M. Blumberg^{1,8}, David Benkeser⁵, Dean P. Jones¹, Charles Peloquin⁹, Russell R. Kempker¹.

¹Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

²National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

³The University of Georgia, Tbilisi, Georgia

⁴David Tvildiani Medical University, The University of Georgia, Tbilisi, Georgia National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

⁵Department of Biostatistics, Rollins School of Public Health of Emory University, Atlanta, Georgia, USA

⁶Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

⁷European University, Tbilisi, Georgia

⁸Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

⁹Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

*** Correspondence:**

Name: Jeffrey Collins, MD, MPH, MSc Email: jeffrey.michael.collins@emory.edu Keywords: tuberculosis, meningitis, metabolomics, cytokines, CSF Running Title: Pharmacometabolomics in TB Meningitis Article Type: Research Article

Abstract

 Poor penetration of many anti-tuberculosis (TB) antibiotics into the central nervous system (CNS) is thought to be a major driver of morbidity and mortality in TB meningitis (TBM). While the amount of a particular drug that crosses into the cerebrospinal fluid (CSF) varies from person to person, little is known about the host factors associated with interindividual differences in CSF concentrations of anti-TB drugs. In patients 7 diagnosed with TBM from the country of Georgia (n=17), we investigate the association between CSF concentrations of anti-TB antibiotics and multiple host factors including serum drug concentrations and CSF concentrations of metabolites and cytokines. We found >2-fold differences in CSF concentrations of anti-TB antibiotics from person to person for all drugs tested including cycloserine, ethambutol, imipenem, isoniazid, levofloxacin, linezolid, moxifloxacin pyrazinamide, and rifampin. While serum drug concentrations explained over 40% of the variation in CSF drug concentrations for 14 cycloserine, isoniazid, linezolid, and pyrazinamide (adjusted R^2 >0.4, p<0.001 for all), there was no evidence of an association between serum concentrations of imipenem and ethambutol and their respective CSF concentrations. CSF concentrations of carnitines were significantly associated with concentrations of ethambutol and imipenem (q<0.05), and imipenem was the only antibiotic significantly associated with CSF cytokine concentrations. These results indicate that there is high interindividual variability in CSF drug concentrations in patients treated for TBM, which is only partially explained by differences in serum drug concentrations and not associated with concentrations of cytokines and chemokines in the CSF.

24 **Introduction**

 Tuberculosis meningitis (TBM) is the most lethal manifestation of tuberculosis 26 (TB) disease, with a mortality rate \geq 25% in those with drug susceptible disease and $>65\%$ in persons with drug resistance.^{1,2} Therapeutic options for TBM are more limited than in other forms of TB due to poor penetration of many anti-TB drugs into the central 29 nervous system (CNS) .^{1,3-5} However, the concentration of antibiotics in the CNS can vary widely by antibiotic and from person to person, indicating certain endotypes exist that lead to favorable CNS penetration of drugs. While it is generally thought that meningeal inflammation increases the CNS concentration of antibiotics, there is limited 33 empirical evidence supporting this concept in TBM.⁶ Further, little is known about the specific inflammatory signaling networks in TBM that may modulate CNS penetration of anti-TB chemotherapeutic agents. An improved understanding of host responses associated with CNS penetration of anti-TB drugs could help inform new strategies to enhance drug delivery to the site of disease in TBM.

 Recent advances in metabolomics and high-density cytokine measurement allow for high-resolution immunometabolic profiling of a variety of human samples including 40 cerebrospinal fluid (CSF).⁷ Such profiling allows for simultaneous measurement of over $\,$ 30 cytokines and thousands of metabolites, including xenobiotics⁸ and molecules that 42 regulate inflammation.^{9,10} Combining measurement of these host response molecules with drug concentrations at the site of disease has the potential to elucidate metabolic and inflammatory processes that regulate drug concentrations and efficacy in TBM; an 45 approach termed pharmacometabolomics.¹¹

 In a well characterized population of patients from the country of Georgia diagnosed and treated for TBM, we integrated data on serum and CSF concentrations 48 of anti-TB antibiotics⁵ and CSF concentrations of metabolites and cytokines.⁷ By integrating these data sets, we sought to address multiple knowledge gaps that currently exist with regard to antibiotic therapy for TB meningitis as follows: 1) the degree of interindividual variability in CSF drug concentrations, 2) whether variation in serum drug concentrations explain the variation in CSF drug concentrations, 3) whether untargeted metabolomics can be used to accurately measure concentrations of TB antibiotics in the CNS, and 4) whether individual differences in the CSF milieu of soluble immunometabolic mediators (i.e. metabolites and cytokines) are associated with CSF drug concentrations of different anti-TB drugs.

RESULTS

Participants

 We studied CSF samples from 17 participants with suspected TBM presenting to the National Center for Tuberculosis and Lung Diseases (NCTLD) (**Table 1**). Among the 17 patients with suspected TBM, five (29%) were microbiologically confirmed while three (18%) were considered to have probable TBM and nine (53%) were considered to 63 have possible TBM based on clinical and laboratory criteria.^{12,13} The median CSF white 64 blood cell (WBC) count at diagnosis was 209 cells/mm³ (IQR 130-286), with 94% lymphocytes (IQR 85-96), a median glucose of 40 mg/dL (IQR 21-50), and total protein of 99 mg/dL (IQR 66-132). Antibiotic regimens were selected by treating clinicians 67 based on NCTLD guidelines and response to treatment as previously reported.^{5,14} Five persons with TBM were deemed to have a poor initial response to treatment, two of

whom were diagnosed with multi-drug-resistant (MDR)-TBM based on microbiologic

testing.

Variation in CSF Concentrations of Anti-TB Drugs

 We first sought to characterize the interindividual variability of anti-TB drug concentrations in the CSF. As per standard of care for patients hospitalized with TBM at NCTLD, lumbar punctures were performed at diagnosis (baseline) and approximately 7, 14, and 28 days after TBM treatment initiation and monthly for as long as patients were 76 hospitalized to follow CSF cell and protein counts in response to treatment.^{5,14} Due to differences between participants in the number of antibiotic doses received at the time of the baseline CSF sample, only samples obtained ≥7 days after treatment start were included in this analysis. Antibiotic concentrations were quantified in the serum and CSF at each time point either 2 or 6 hours after the most recent antibiotic dose as previously 81 described.⁵ A 2- to 4-fold difference in CSF drug concentrations was found between participants at 2 hours (**Figure 1A-I**) and 6 hours (**Figure 2A-I**) after the dosing of anti- TB antibiotics. This was observed across antibiotics, indicating a large amount of interindividual variability in CSF drug concentrations regardless of the drug used. There are multiple sources of potential interindividual variability in CSF drug concentrations among patients with TBM including integrity of the blood-brain and blood-CSF barriers, variability in protein binding, and differential expression of drug 88 transporters.¹⁵ TB drugs are also known to have large differences in serum concentration from person to person, which could explain some or all of the variability in 90 CSF drug concentrations.¹⁶ To examine this possibility, we sought to determine how well concomitantly collected serum drug concentrations explained the variation in CSF

 drug concentrations using a mixed effects linear model. We found the relationship between plasma and CSF drug concentrations varied substantially from drug to drug. 94 For cycloserine, isoniazid, and linezolid, we calculated an adjusted R^2 of >0.5, suggesting serum drug concentrations explained over 50% of the variability in CSF drug concentrations (**Figure 3A-C**). For other drugs including pyrazinamide, levofloxacin, and rifampin, serum drug concentrations explained a statistically significant amount of 98 variation in CSF concentrations, but the adjusted R^2 values were 0.4, 0.23 and 0.19 respectively (**Figure 3D-F**). For moxifloxacin, imipenem, and ethambutol, serum drug concentrations were not significantly associated with CSF drug concentrations (**Figure 3G-I**).

Using Untargeted Metabolomics to measure CSF Drug Concentrations

 We performed untargeted high-resolution metabolomics on CSF samples using combined liquid chromatography-mass spectrometry in dual ionization mode with HILIC positive and c18 negative chromatography (see Methods for full details). We detected 6,596 metabolic features in positive ionization mode and 9,427 in negative ionization mode. We then performed a targeted search for molecular features that were within a mass and retention time error range of 5 ppm and 30 seconds respectively for the M+H or M-H adducts of anti-TB drugs. This query yielded high confidence matches for several anti-TB drugs including ethambutol, isoniazid, pyrazinamide, rifampin, linezolid, imipenem, levofloxacin, and moxifloxacin. We then performed a correlation analysis of the peak intensity for each annotated metabolite and the antibiotic concentration as 113 measured using MS/MS and a purified standard curve.⁵ We found that the intensity value for each antibiotic as measured by our untargeted metabolomics platform was

 strongly correlated with the absolute concentration of most anti-TB antibiotics in the CSF. Peaks for ethambutol, pyrazinamide, isoniazid, linezolid, and imipenem all demonstrated a Pearson correlation coefficient of >0.7 when compared with absolute drug concentrations (**Figure 4A-E**; p<0.001 for all). The peak intensity for moxifloxacin (r=0.53, p=0.05) and levofloxacin (r=0.45, p<0.001), as well as rifampin (r=0.48, p<0.001), were also significantly correlated with measured CSF concentrations, but the relationship was less strong than for the other antibiotics studied (**Figure 4F-H**). In the case of rifampin, this may have been due in part to the relatively low concentration of this antibiotic in the CSF. These data indicate that untargeted metabolomics can be an effective method to approximate many anti-TB drug concentrations in biofluids. **Relationship Between CSF Metabolism, Inflammation, and Drug Concentrations** Antibiotic penetration into the CSF is generally thought to be increased when there is a breakdown in the blood-brain barrier due to meningeal inflammation in 128 persons with TBM.¹⁷ We therefore sought to mine concomitantly collected high- resolution metabolomics and cytokine data to determine whether any soluble immune mediators were associated with CSF drug concentrations. We used mixed effects linear models to determine which cytokines and metabolites with known chemical identities were most strongly associated with CSF concentrations of each antibiotic. In **Figure 5**, we show the metabolites and cytokines significantly associated with the concentration of at least one antibiotic using a false discovery correction of q<0.05. We found that carnitines were significantly associated with CSF concentrations of ethambutol and imipenem at q<0.05, as well as isoniazid, linezolid, pyrazinamide, and rifampin at an unadjusted p<0.05. However, the directionality of the association was inconsistent.

 While increased CSF concentrations of carnitines were associated with increased concentrations of ethambutol and imipenem, they were associated with lower CSF concentrations of isoniazid, linezolid, pyrazinamide, and rifampin. This suggests that different metabolic states in the CNS may be associated with increased drug penetration for certain classes of antibiotics while decreasing CSF drug concentrations for others. There were few significant associations between cytokine and antibiotic concentrations in the CNS. Increased concentrations of pro-inflammatory cytokines and chemokines including TNF-a, MCP-3, IL-6, IL-18, and IFN-y were associated with

increased concentrations of imipenem, but otherwise had little relationship to CSF

antibiotic concentrations. The only exception was IL-6, which was significantly

associated with CSF ethambutol concentrations. These data indicate that an

inflammatory CSF milieu had minimal impact on CSF concentrations anti-TB antibiotics.

DISCUSSION

 In this TBM pharmacometabolomics study, we show there is significant interindividual variability in CSF concentrations of anti-TB antibiotics. We further show that differences in serum drug concentrations account for much of the variability in CSF concentrations of linezolid, isoniazid, and cycloserine, but have a less strong relationship with CSF concentrations of imipenem, rifampin, moxifloxacin, and ethambutol. Finally, we demonstrate that CSF drug concentrations may be affected by the CSF metabolic milieu and have little association with concentrations of proinflammatory cytokines and chemokines. Together, these data show that a complex mix of factors contribute to CSF concentrations of anti-TB antibiotics. For many antibiotics, factors such as CNS inflammation and serum concentrations, which are traditionally thought to be primary drivers of drug concentrations in the CNS, may play only a minor role.

 While serum concentrations of anti-TB drugs are known to vary widely from 166 person to person,¹⁶ we show equally wide variability in CSF drug concentrations in those treated for TBM. Across the study population we found greater than 2-fold differences in CSF concentrations of all anti-TB drugs studied. This was true both two and six hours after the dose of each drug. Such variability in the CSF concentrations of anti-TB drugs has been shown in other studies, most notably among 237 patients (>700 CSF samples) included in a pharmacology sub study evaluating rifampin, isoniazid, and 172 levofloxacin CSF concentrations.¹⁸ The substantial variation in CSF concentrations among study participants was evidenced by large 95% confidence intervals for both $\,$ C_{max} and AUC parameters.¹⁸ Furthermore, interpatient variability in CSF rifampin¹⁹ and 175 fluoroquinolone²⁰ concentrations have been demonstrated in clinical trial dose finding and drug comparison studies, respectively. What has been less studied, is clinical or laboratory predictors of CSF drug concentrations. We found that serum concentrations are poorly predictive of CSF concentrations for many drugs including imipenem, 179 rifampin, moxifloxacin, and ethambutol. Using the plasma rifampin AUC_{0-24} parameter, Dian et al, found a high correlation between plasma and CSF rifampin concentrations 181 (Spearman's ρ 0.7, p<.01).¹⁹ A better understanding of predictors of CSF drug penetration is needed to help both understand the underlying mechanisms of drugs

 reaching the site of disease and also to identify clinically useful markers to help guide optimal drug doing in TBM.

 This study provides evidence that untargeted, high-resolution metabolomics can be an accurate way to capture drug concentrations of multiple anti-TB drugs including imipenem, ethambutol, isoniazid, linezolid, and pyrazinamide. This result is supported by studies showing untargeted metabolomics can also be an accurate way to capture 189 exposure to xenobiotics in the environment. The ability to accurately quantify drug concentrations as part of an untargeted metabolomics platform is likely to create additional opportunities to understand drug concentrations and pharmacokinetics in the context of broader measurement of host metabolism. Understanding broad host metabolic responses to drugs, termed "pharmacometabolomics", is an emerging area of study with great potential to improve our understanding of heterogenous host responses to medications including antibiotics and enhance personalized medicine.¹¹ However, a limitation of the approach has been the need to separately perform targeted quantification of drugs and untargeted metabolomics. Our findings suggest that in many cases, important insights in pharmacometabolomics could be obtained from untargeted metabolomics data alone.

 By simultaneously collecting pharmacology, metabolomics, and cytokine data in the present study, we were able to examine which soluble immune and metabolic mediators in CSF are associated with improved CNS penetration of TB drugs. The association between CSF concentrations of multiple antibiotics and carnitines suggests that a metabolic milieu with increased oxidative phosphorylation may impact antibiotic penetration in the CNS. Increased carnitines in the CSF, which transport fatty acids

 from the cytosol into mitochondria to be oxidized, may reflect improved cellular function and lower levels of glycolysis, which tends to produce greater inflammatory signaling in 208 immune cells. $9,21,22$ Historically, greater inflammation in the CNS has been thought to be 209 a catalyst for drug penetration across blood-brain and blood-CSF barriers.¹⁷ The present study found little relationship between CSF drug concentrations and pro- inflammatory cytokines. While elevated CSF concentrations of cytokines does not necessarily indicate increased meningeal inflammation, the findings do suggest that the relationship between CSF drug concentrations and inflammation is minimal. This is supported by prior work from our group, which indicated CSF concentrations of anti-TB drugs are roughly equal early in the course TBM treatment versus two or more months after treatment start, when meningeal inflammation would be expected to decrease.⁵ However, another explanation for these findings is that the CSF milieu remains highly 218 inflammatory months after treatment start,⁷ which could mean CNS drug penetration is enhanced for an extended period of time.

 This study is subject to several limitations. The small sample size of persons with TBM and low number of microbiologically confirmed cases from a single geographic region available for analysis in this study may limit generalizability. Further, the robustness of statistical inferences from such a small sample is limited. Though we demonstrate a strong association between CSF concentrations of multiple metabolites and concentrations of anti-TB drugs, the observational nature of the study precludes us from establishing a causal relationship. In future studies it will be important to evaluate 227 the links between key metabolites and CSF drug penetration using animal models of TBM and larger, diverse human cohorts. Enhancing our understanding of how soluble

 mediators in the CNS impact drug penetration may lead to therapies that enhance drug delivery to this area or personalized dosing regimens for individual patients. Overall, this study shows the interindividual variation in CSF drug concentrations among persons with TBM is high and potentially linked to the metabolic milieu of the CSF. Serum drug concentrations are only weakly associated with CSF concentrations for some drugs, and the amount of inflammation in the CSF appears to have only a minor role in enhancing drug penetration. Our results provide insight into the factors that impact CSF drug concentrations in TBM and indicate that improved understanding of the host metabolic response could provide targets to enhance drug delivery. **MATERIAL AND METHODS Setting and Participants with TBM** Persons with TBM were enrolled from the National Center for Tuberculosis and Lung Diseases (NCTLD) in Tbilisi, Georgia as part of a clinical pharmacology study 243 evaluating the penetration of anti-TB drugs into the CNS.⁵ Patients aged ≥16 years treated in the NCTLD adult TBM ward from January 2018 to December 2019 were eligible for inclusion. All patients suspected of having TBM underwent a lumbar puncture; acid-fast bacilli (AFB) staining, liquid and solid culture, and Xpert MTB/RIF assay were performed on CSF. As per standard of care for patients hospitalized with TBM at NCTLD, lumbar punctures were performed at approximately 7, 14, and 28 days after TBM treatment initiation and monthly for as long as patients were hospitalized to 250 follow CSF cell and protein counts in response to treatment.^{5,14} Treatment regimens were selected by treating clinicians based on treatment history, comorbidities, and drug

252 susceptibility results when available.¹⁴ All patients also received a $6-8$ -week course of dexamethasone (400-1200 mg). Written informed consent was obtained from all study participants, and study approval was obtained from the institutional review boards of

- Emory University and the NCTLD.
- **Sample Collection and Drug Quantification**

 Blood samples were collected at 2 and 6 hours after drug administration at each timepoint. For CSF collection, 3 mL was collected at each time point, alternating between 2 and 6 hours after drug administration to capture early and delayed drug 260 penetration into the CSF. All centrifuged blood as well as CSF samples were stored at – 80°C at the NCTLD until shipped to the Infectious Diseases Pharmacokinetic Laboratory at the University of Florida, where drug concentrations were quantified. Total concentrations of each drug were measured using validated liquid chromatography tandem mass spectrometry assays. The assays were validated for human plasma, and cross checked for matrix effects using artificial CSF. The analyses were performed on Thermo Scientific TSQ Endura or TSQ Quantum Ultra mass spectrometers.

Metabolomics analysis

 De-identified CSF samples were randomized by a computer-generated list into blocks of 40 samples prior to transfer to the analytical laboratory where personnel were blinded to clinical and demographic data. Thawed CSF (65 μL) was treated with 130 μl acetonitrile (2:1, v/v) containing an internal isotopic standard mixture (3.5 μL/sample), 272 as previously described. 23 Samples were centrifuged and supernatants were analyzed using an Orbitrap Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA, USA) with dual HILIC positive and c18 negative liquid chromatography (Higgins

 Analytical, Targa, Mountain View, CA, USA, 2.1 x 10 cm) with a formic acid/acetonitrile gradient. The high-resolution mass spectrometer was operated over a scan range of 85 277 to 1275 mass/charge (m/z) .²⁴ Data were extracted and aligned using apLCMS 25 and 278 xMSanalyzer ²⁶ with each feature defined by specific *m/z* value, retention time, and 279 integrated ion intensity. Three technical replicates were performed for each CSF sample and intensity values were median summarized.

Cytokine detection

 The commercially available U-PLEX assay by Meso Scale Discovery (MSD) was used for CSF cytokine detection. This assay allows for the evaluation of multiplexed biomarkers by using custom made U-PLEX sandwich antibodies with a SULFO-TAG conjugated antibody and electrochemiluminescence (ECL) detection. Direct quantitation of cytokines was performed using standard curves generated by 4-fold serial dilutions of standard calibrators provided by MSD. Plates were read on the QuickPlex SQ 120 using 288 Methodical MindTM software and plate data analyzed using Discovery WorkbenchTM 289 software (MSD). $27,28$

Statistical Analysis

 Descriptive statistics were provided for baseline characteristics, and the concentrations of anti-TB antibiotics in patients' CSF were summarized for each drug at both 2-hour and 6-hour time points following the most recent antibiotic dose. We applied 294 a linear mixed regression model, adjusting for sampling time (2 or 6 hours), and reported the adjusted R-squared values of each pairwise comparison of models, 296 whether they included or excluded serum concentration²⁹. Similarly, to determine associations between CSF drug concentrations and metabolite and cytokine

Acknowledgments

 The authors thank the physicians, nurses, and staff at the NCTLD in Tbilisi, Georgia, who provided care for the patients with TBM included in this study. Additionally, the authors are thankful for study participants with tuberculosis meningitis who were willing to participate in the study and help contribute meaningful data that may help future patients with the same illness.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial

or financial relationships that could be construed as a potential conflict of interest.

Funding

This work was supported by grants from the National Institutes of Health (NIH) and

National Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044,

References

- 1. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol.
- 2017;13(10):581-598.
- 2. Evans EE, Avaliani T, Gujabidze M, et al. Long term outcomes of patients with
- tuberculous meningitis: The impact of drug resistance. PLoS One.
- 2022;17(6):e0270201.
- 3. Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients With
- Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis
- Regimen. Clin Infect Dis. 2017;65(1):20-28.
- 4. Vinnard C, King L, Munsiff S, et al. Long-term Mortality of Patients With Tuberculous
- Meningitis in New York City: A Cohort Study. Clin Infect Dis. 2017;64(4):401-407.
- 5. Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for
- Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. Clin Infect
- Dis. 2022;75(4):682-689.
- 6. Nau R, Seele J, Djukic M, Eiffert H. Pharmacokinetics and pharmacodynamics of
- antibiotics in central nervous system infections. Curr Opin Infect Dis. 2018;31(1):57-68.
- 7. Tomalka J, Sharma A, Smith AGC, et al. Combined cerebrospinal fluid metabolomic
- and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes
- in immunometabolic networks. Tuberculosis. 2023. *In press*.
- 8. Liu KH, Lee CM, Singer G, et al. Large scale enzyme based xenobiotic identification for exposomics. Nat Commun. 2021;12(1):5418.
- 9. Collins JM, Jones DP, Sharma A, et al. TCA cycle remodeling drives proinflammatory
- signaling in humans with pulmonary tuberculosis. PLoS Pathog. 2021;17(9):e1009941.

- 10. Collins JM, Siddiqa A, Jones DP, et al. Tryptophan catabolism reflects disease
- activity in human tuberculosis. JCI Insight. 2020;5(10).
- 11. Beger RD, Schmidt MA, Kaddurah-Daouk R. Current Concepts in
- Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. Metabolites.
- 2020;10(4).
- 12. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case
- definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-812.
- 13. Marais BJ, Heemskerk AD, Marais SS, et al. Standardized Methods for Enhanced
- Quality and Comparability of Tuberculous Meningitis Studies. Clin Infect Dis.
- 2017;64(4):501-509.
- 14. Smith AGC, Gujabidze M, Avaliani T, et al. Clinical outcomes among patients with
- tuberculous meningitis receiving intensified treatment regimens. Int J Tuberc Lung Dis.
- 2021;25(8):632-639.
- 15. Dian S, Ganiem AR, van Laarhoven A. Central nervous system tuberculosis. Curr
- Opin Neurol. 2021;34(3):396-402.
- 16. Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.
- Microbiol Spectr. 2017;5(1).
- 17. Haddad N, Carr M, Balian S, et al. The Blood-Brain Barrier and
- Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of
- Central Nervous System Infections in Adults. Antibiotics (Basel). 2022;11(12).
- 18. Ding J, Thuy Thuong Thuong N, Pham TV, et al. Pharmacokinetics and
- Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis.
- Clin Pharmacol Ther. 2020;107(4):1023-1033.

- 19. Dian S, Yunivita V, Ganiem AR, et al. Double-Blind, Randomized, Placebo-
- Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for
- Tuberculous Meningitis. Antimicrob Agents Chemother. 2018;62(12).
- 20. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and
- pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
- Antimicrob Agents Chemother. 2011;55(7):3244-3253.
- 21. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, et al. Cutting Edge:
- Mycobacterium tuberculosis Induces Aerobic Glycolysis in Human Alveolar
- Macrophages That Is Required for Control of Intracellular Bacillary Replication. J
- Immunol. 2016;196(6):2444-2449.
- 22. Olson GS, Murray TA, Jahn AN, et al. Type I interferon decreases macrophage
- energy metabolism during mycobacterial infection. Cell Rep. 2021;35(9):109195.
- 23. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. High-
- performance metabolic profiling with dual chromatography-Fourier-transform mass
- spectrometry (DC-FTMS) for study of the exposome. Metabolomics. 2013;9(1
- Suppl):S132-143.
- 24. Go YM, Walker DI, Liang Y, et al. Reference Standardization for Mass Spectrometry
- and High-Resolution Metabolomics Applications to Exposome Research. Toxicol Sci.
- 2015;148(2):531-542.
- 25. Yu T, Park Y, Johnson JM, Jones DP. apLCMS--adaptive processing of high-
- resolution LC/MS data. Bioinformatics (Oxford, England). 2009;25(15):1930-1936.

- 26. Uppal K, Soltow QA, Strobel FH, et al. xMSanalyzer: automated pipeline for
- improved feature detection and downstream analysis of large-scale, non-targeted
- metabolomics data. BMC Bioinformatics. 2013;14:15.
- 27. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses
- for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47.
- 28. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance
- testing. Statistics in medicine. 1990;9(7):811-818.
- 29. Nagelkerke NJD. A note on a general definition of the coefficient of determination.
- Biometrika. 1991;78(3):691-692.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

433 **Tables and Figure Legends (Figure files submitted separately)**

434 **Table 1**

435

436

437

438

439

440

441

442

443

 Figure 1 – Boxplots depicting median cerebrospinal fluid concentrations of anti-TB antibiotics 2 hours after the most recent antibiotic dose for 17 study participants: (A) cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid, (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin. **Figure 2 –** Boxplots depicting median cerebrospinal fluid concentrations of anti-TB antibiotics 6 hours after the most recent antibiotic dose for 17 study participants: (A) cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid, (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin. **Figure 3 –** Scatter plots with fitted regression lines depicting the relationship between serum and cerebrospinal fluid concentrations of anti-TB drugs: (A) cycloserine, (B) isoniazid, (C) linezolid, (D) pyrazinamide, (E) levofloxacin, (F) rifampin, (G) moxifloxacin, (H) imipenem, and (I) ethambutol. For each figure, r represents the 458 correlation coefficient with corresponding p-value. The adjusted R^2 was calculated using a mixed effects linear model, adjusting for sampling time (2 or 6 hours), with p-values derived from the pairwise comparison of models including and excluding the serum concentration of each drug.

Figure 4 – Scatter plots with fitted regression lines depicting the relationship between

- cerebrospinal fluid concentrations of anti-TB drugs and their mass spectrometry
- intensity value as measured on the untargeted metabolomics platform: (A) ethambutol,
- (B) isoniazid, (C) linezolid, (D) imipenem, (E) pyrazinamide, (F) moxifloxicin, (G)
- rifampin, and (H) levofloxacin. For each figure, r and p values are based on the Pearson
- correlation coefficient for each drug.
-
- \blacktriangleright **Figure 5 –** The bubble plots represent the adjusted R² values measuring the
- association between anti-TB drug concentrations and soluble immune mediators
- (metabolites, cytokines, and chemokines) in the cerebrospinal fluid. The color scale for
- 476 each dot represents the adjusted R^2 value and dot size represents the –log P value for
- each association.

A

 \Box

 \blacktriangleleft

 $\boldsymbol{\mathsf{\Omega}}$

